Ivonescimab – Talk Bio

Updated Efficacy Data of Ivonescimab Plus Chemotherapy as First-Line Treatment for TNBC at ESMO IO 2025

16 hours ago talkbio0Tagged AK112 - 308, Breakthrough Therapy Designation, Combined, Complex partial seizures, disease control rate, ESMO IO, First line treatment, Frequency of Responses, HARMONi-BC1, Ivonescimab, PD-1/VEGF bispecific antibody, PD-L1, Pharmacotherapy, Phase 2 Clinical Trials, Progression-Free Survival, safety profile, Subgroup A Nepoviruses, TNBC, Triple Negative Breast Neoplasms, Yidafan

ivonescimab; Yidafan; PD-1/VEGF bispecific antibody; triple-negative breast cancer; TNBC; first-line treatment; ESMO IO 2025; Phase II trial; chemotherapy combination; objective response rate; progression-free survival; disease control rate; PD-L1 CPS subgroups; safety profile; Breakthrough Therapy Designation; HARMONi-BC1; AK112-308

Akeso, Summit’s PD-1xVEGF Drug Ivonescimab Shows Strong Progression-Free Survival Benefit in Global Lung Cancer Trial

4 months ago talkbio0Tagged Akeso, Antibodies, Bispecific, Approved, Ivonescimab, Non-Small Cell Lung Carcinoma, Overall Survival, PD-1xVEGF, Phase 3 trial, Progression-Free Survival, summit, United States Food and Drug Administration

Akeso; Summit Therapeutics; ivonescimab; PD-1xVEGF; bispecific antibody; non-small cell lung cancer; progression-free survival; Phase 3 trial; overall survival; FDA approval

‘Deviated from the core’: Akeso CEO tries to reset expectations of bispecific’s survival readout amid market tumult

8 months ago talkbio0Tagged Antibodies, Bispecific, Ivonescimab, Keytruda, Keytruda head-to-head trial, Market, Non-Small Cell Lung Carcinoma, Overall Survival, PD-1xVEGF, Reaction, summit

Ivonescimab, PD-1xVEGF bispecific antibody, Overall survival (OS) readout, Keytruda head-to-head trial, HARMONi-2 trial, Non-small cell lung cancer (NSCLC), Market reaction, Summit Therapeutics